Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.

High intra-, postoperative complication risks in patients with obesity and ulcerative colitis

Roshini Claire Anthony
22 Jan 2019

Patients with obesity have an elevated risk of intra- and postoperative complications following surgical treatment for inflammatory bowel disease (IBD), according to a presentation at the recent Advances in Inflammatory Bowel Disease meeting (AIBD 2018).

The prevalence of obese patients with IBD is increasing, with research showing that 15–40 percent of patients with IBD are obese, while an additional 20–40 percent are overweight, [Nat Rev Gastroenterol Hepatol 2017;14:110-121] presented Dr Nicole Lopez from the University of California San Diego Health in La Jolla, California, US.

Obesity has implications on surgical management of ulcerative colitis which include longer operation time, increased perioperative morbidity, reduced technical ability to create an ilieal pouch-anal anastomosis (IPAA), and increased risk of conversion to open surgery or postoperative complications, said Lopez. In particular, patients with obesity who undergo laparoscopic colorectal surgery also have an elevated risk of blood loss and visceral injury as well as a shorter specimen length. [Dis Colon Rectum 2017;60:433-445]

In a study conducted among 1,175 patients who were scheduled to undergo IPAA for ulcerative colitis, 23 patients could not undergo the procedure due to obesity. The study found a higher risk of technical inability to perform the IPAA procedures among patients with elevated BMI (odds ratio, 1.26, 95 percent confidence interval, 1.17–1.34; p<0.001), with the rate of unsuccessful IPAA procedures rising with higher BMIs (2.0, 5.7, and 15.0 percent for BMI 30, 35, and 40 kg/m2, respectively; p<0.01). [Dis Colon Rectum 2016;59:1034-1038]

A separate retrospective review conducted among 103 and 75 non-obese and obese patients, respectively, with ulcerative colitis found a higher rate of complications among obese patients than non-obese ones (BMI ≥30 vs <30 kg/m2; 80 percent vs 64 percent; p=0.03), specifically pouch-related complications such as anastomotic or pouch strictures (27 percent vs 6 percent; p<0.01), inflammatory pouch complications (17 percent vs 4 percent; p<0.01), and pouch fistulas (12 percent vs 3 percent; p=0.03). [J Gastrointest Surg 2014;18:573-579]

Another retrospective study looking at long-term outcomes post-IPAA in patients with ulcerative colitis found that obese patients were less likely to undergo laparoscopic IPAA procedures than non-obese patients (47.1 percent vs 73.4 percent; p<0.0001 and 15.8 percent vs 29.4 percent; p=0.03 for stage 2 and 3 procedures, respectively), had longer operative times (288.7 vs 270.1 min; p=0.02 and 237.7 vs 200.5 min; p=0.0002, respectively), higher estimated blood loss (271.2 vs 205.6 mL; p=0.005 and 301.1 vs 186.1 mL; p<0.0001, respectively), and longer hospital stay (8.8 vs 7.6 days; p=0.03 for stage 2 procedures). [Inflamm Bowel Dis 2017;23:2142-2146]

“Obesity impacts intraoperative complexity and 30-day postoperative outcomes while long-term functional outcomes are not affected,” said Lopez.

“So all in all we can see that incisional hernias, pouch complications, anastomotic or pouch strictures, and inflammatory pouch complications are more common in obese patients, as is longer operation time, prolonged inpatient stay, wound infection, and anastomotic leak,” said Lopez.

A solution to this problem is to encourage weight loss in this group of patients with bariatric surgery as a potential method, she said.

A study from the Netherlands showed that bariatric surgery appeared to be safe and effective in patients with ulcerative colitis or Crohn’s disease. There were no deaths or major perioperative complications among the 45 patients in the study, while two major complications (gastro-enterostomy bleeding and pyelonephritis with secondary pancreatitis) occurred during follow up in two patients with Crohn’s disease. [Obes Surg 2018;28:1681-1687]

However, it is important for surgeons to anticipate reach problems in patients with obesity and subsequently adjust their techniques to gain adequate reach, said Lopez.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.